In surveying clinical trials that have been or currently are in the testing phase for BTK inhibitors, we found that indication selection has been biased towards the treatment of the rheumatic diseases RA and SLE, with a few trials also conducted for the treatment of MS, PV, SJ, CSU, IP, GVHD, and asthma. Here, BTK is linked to graft versus host disease.